Table 2 Switch, discontinuation, and continuation rates of second bDMARD therapies
| Â | Full patient population [n (%, 95%-CI)] | Patients with anti-TNFs as second bDMARD [n (%, 95%-CI)] | Patients with non-anti-TNFs as second bDMARD [n (%, 95%-CI)] | Difference in percentage points, p-value (anti-TNF versus non-anti-TNF) | |||
|---|---|---|---|---|---|---|---|
Observed patients | 451 | (100.0%) | 340 | (100.0%) | 111 | (100.0%) | Â |
Switchers | 111 | (24.6%, 95%-CI: 20.8–28.8) | 98 | (28.8%, 95%-CI: 24.2–33.9) | 13 | (11.7%, 95%-CI: 6.9–19.2) | −17.1%, p < 0.001 |
Discontinuers (90 day gap) | 85 | (18.8%, 95%-CI: 15.5–22.7) | 61 | (17.9%, 95%-CI: 14.2–22.4) | 24 | (21.6%, 95%-CI: 14.9–30.3) | 3.7%, p = 0.403 |
Among discontinuers (90 day gap): patients who re-started therapy | 15 | (17.6%, 95%-CI: 10.8–27.5) | 13 | (21.3%, 95%-CI: 12.6–33.6) | 2 | (8.3%, 95%-CI: 2.0–29.0) | −13.0%, p = 0.158 |
Continuers (90 day gap) | 256 | (56.8%, 95%-CI: 52.1–61.3) | 182 | (53.5%, 95%-CI: 48.2–58.8) | 74 | (66.7%, 95%-CI: 57.3–74.9) | 13.2%, p = 0.015 |
Discontinuers (180 day gap) | 67 | (14.9%, 95%-CI: 11.9–18.5) | 45 | (13.2%, 95%-CI: 10.0–17.3) | 22 | (19.8%, 95%-CI: 13.4–28.3) | 6.6%, p = 0.093 |
Continuers (180 day gap) | 273 | (60.5%, 95%-CI: 55.9–65.0) | 197 | (57.9%, 95%-CI: 52.6–63.1) | 76 | (68.5%, 95%-CI: 59.2–76.5) | 10.6%, p = 0.045 |